{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:23Z","timestamp":1792979903214,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mutation Research - Reviews in Mutation Research"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.mrrev.2025.108533","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T06:42:58Z","timestamp":1738824178000},"page":"108533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A tale of two drugs: Molnupiravir and Paxlovid"],"prefix":"10.1016","volume":"795","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9238-7916","authenticated-orcid":false,"given":"Michael D.","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stafford G.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(23)00493-0","article-title":"Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial","volume":"24","author":"Schilling","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.mrrev.2025.108533_bib2","article-title":"Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study","volume":"41","author":"Van Heer","year":"2023","journal-title":"Lancet Reg. Health - West. Pac."},{"issue":"10","key":"10.1016\/j.mrrev.2025.108533_bib3","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1111\/dom.15830","article-title":"Comparing the effectiveness of molnupiravir and nirmatrelvir-ritonavir in non-hospitalized and hospitalized COVID-19 patients with type 2 diabetes: a target trial emulation study","volume":"26","author":"Wan","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"10373","key":"10.1016\/j.mrrev.2025.108533_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"issue":"News and Views","key":"10.1016\/j.mrrev.2025.108533_bib5","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/d41586-023-03248-3","article-title":"Darren, Anti-COVID drug accelerates viral evolution.","volume":"623","author":"Kosakovsky Pond","year":"2023","journal-title":"Nature"},{"issue":"7948","key":"10.1016\/j.mrrev.2025.108533_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/d41586-023-00347-z","article-title":"COVID drug drives viral mutations - and now some want to halt its use","volume":"614","author":"Callaway","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100770","article-title":"Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template","volume":"297","author":"Gordon","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108533_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41594-021-00657-8","article-title":"Molnupiravir: coding for catastrophe","volume":"28","author":"Malone","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7987","key":"10.1016\/j.mrrev.2025.108533_bib9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41586-023-06649-6","article-title":"A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes","volume":"623","author":"Sanderson","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108533_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/em.22471","article-title":"Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir","volume":"63","author":"Waters","year":"2022","journal-title":"Environ. Mol. Mutagen"},{"issue":"6580","key":"10.1016\/j.mrrev.2025.108533_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1126\/science.abn0048","article-title":"Lethal mutagenesis as an antiviral strategy","volume":"375","author":"Swanstrom","year":"2022","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-023-01392-w","article-title":"A new generation M(pro) inhibitor with potent activity against SARS-CoV-2 Omicron variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.mrrev.2025.108533_bib14","first-page":"107","article-title":"W., M, Pathogen Genomics and Host cellular Susceptibility Factors. Glob Clin","volume":"2","author":"Zhang","year":"2020","journal-title":"Transl. Res"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108533_bib15","first-page":"35","article-title":"W., M Correction: Pathogen Genomics and Host Cellular Susceptibility Factors. Glob Clin","volume":"3","author":"Zhang","year":"2020","journal-title":"Transl. Res"},{"issue":"9","key":"10.1016\/j.mrrev.2025.108533_bib16","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"48","key":"10.1016\/j.mrrev.2025.108533_bib17","doi-asserted-by":"crossref","first-page":"28115","DOI":"10.1039\/D0CP05297C","article-title":"Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19","volume":"22","author":"Jena","year":"2020","journal-title":"Phys. Chem. Chem. Phys."},{"issue":"24","key":"10.1016\/j.mrrev.2025.108533_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01348-19","article-title":"Small-Molecule Antiviral \u03b2-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"issue":"541","key":"10.1016\/j.mrrev.2025.108533_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb5883","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","volume":"12","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108533_bib20","article-title":"Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity","volume":"14","author":"Hassine","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100867","article-title":"Decoding molnupiravir-induced mutagenesis in SARS-CoV-2","volume":"297","author":"Men\u00e9ndez-Arias","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108533_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040206617738656","article-title":"Nucleoside diphosphate and triphosphate prodrugs - An unsolvable task?","volume":"25","author":"Meier","year":"2017","journal-title":"Antivir. Chem. Chemother."},{"issue":"6","key":"10.1016\/j.mrrev.2025.108533_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1073\/pnas.47.6.845","article-title":"The chemical and mutagenic specificity of hydroxylamine","volume":"47","author":"Freese","year":"1961","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108533_bib24","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0022-2836(65)80024-9","article-title":"Mechanism of the mutagenic action of hydroxylamine","volume":"11","author":"Brown","year":"1965","journal-title":"J. Mol. Biol."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108533_bib25","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1128\/AAC.48.12.4636-4642.2004","article-title":"Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells","volume":"48","author":"Hernandez-Santiago","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.mrrev.2025.108533_bib26","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/AAC.48.2.651-654.2004","article-title":"Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2\u2032-deoxy-2\u2032-fluorocytidine","volume":"48","author":"Stuyver","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/AAC.47.1.244-254.2003","article-title":"Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture","volume":"47","author":"Stuyver","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"515","key":"10.1016\/j.mrrev.2025.108533_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med"},{"issue":"11","key":"10.1016\/j.mrrev.2025.108533_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/v15112151","article-title":"Molnupiravir Revisited-Critical Assessment of Studies in Animal Models of COVID-19","volume":"15","author":"Rasmussen","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.mrrev.2025.108533_bib30","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.mrrev.2025.108533_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2023.108475","article-title":"An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations","volume":"121","author":"Marikawa","year":"2023","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.mrrev.2025.108533_bib32","unstructured":"FDA, U., Fact Sheet for Healthcare Providers: Emergency Use Authorization for Lagevrio (molnupiravir) Capsule. 2021. 2021."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108533_bib33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/17460441.2022.2153828","article-title":"The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)","volume":"17","author":"Pagliano","year":"2022","journal-title":"Expert Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108533_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/em.22510","article-title":"Evaluation of the mutagenic effects of Molnupiravir and N4-hydroxycytidine in bacterial and mammalian cells by HiFi sequencing","volume":"63","author":"Miranda","year":"2022","journal-title":"Environ. Mol. Mutagen"},{"issue":"5","key":"10.1016\/j.mrrev.2025.108533_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02428-20","article-title":"Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2","volume":"65","author":"Painter","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mrrev.2025.108533_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104748","article-title":"Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite \u03b2-D-N4-hydroxycytidine across the blood-placenta barrier","volume":"95","author":"Chang","year":"2023","journal-title":"eBioMedicine"},{"issue":"22","key":"10.1016\/j.mrrev.2025.108533_bib37","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.1093\/nar\/gkad1002","article-title":"Uridine-cytidine kinase 2 potentiates the mutagenic influence of the antiviral \u03b2-d-N4-hydroxycytidine","volume":"51","author":"Xu","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.mrrev.2025.108533_bib38","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jiab362","article-title":"Letter to the Editor in Response to Zhou et al","volume":"224","author":"Troth","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.mrrev.2025.108533_bib39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/infdis\/jiab363","article-title":"Reply to Troth et al","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108533_bib40","first-page":"53","article-title":"Molnupiravir Metabolite--N4 -hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro","volume":"23","author":"Chamod","year":"2023","journal-title":"Asian Med. J. Altern. Med."},{"key":"10.1016\/j.mrrev.2025.108533_bib41","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.toxlet.2022.04.002","article-title":"Genotoxicity assessment of potentially mutagenic nucleoside analogues using ToxTracker(R)","volume":"362","author":"Brandsma","year":"2022","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.mrrev.2025.108533_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/11779322221085077","article-title":"Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment","volume":"16","author":"Githaka","year":"2022","journal-title":"Bioinform Biol. Insights"},{"issue":"9","key":"10.1016\/j.mrrev.2025.108533_bib43","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/jiac477","article-title":"Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir","volume":"227","author":"Kobayashi","year":"2023","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mrrev.2025.108533_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/toxsci\/kfae112","article-title":"Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir","author":"Escobar","year":"2024","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.mrrev.2025.108533_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/em.22427","article-title":"Recommendations for conducting the rodent erythrocyte Pig-a assay: A report from the HESI GTTC Pig-a Workgroup","volume":"62","author":"Dertinger","year":"2021","journal-title":"Environ. Mol. Mutagen"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108533_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/em.22538","article-title":"Determination of a positive response in the Ames Salmonella mutagenicity assay","volume":"64","author":"Zeiger","year":"2023","journal-title":"Environ. Mol. Mutagen"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108533_bib47","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.mrfmmm.2004.08.014","article-title":"Induction of A:T to G:C transition mutations by 5-(2-chloroethyl)-2\u2032-deoxyuridine (CEDU), an antiviral pyrimidine nucleoside analogue, in the bone marrow of Muta\u2122Mouse","volume":"568","author":"Staedtler","year":"2004","journal-title":"Mutat. Res. \/Fundam. Mol. Mech. Mutagen."},{"key":"10.1016\/j.mrrev.2025.108533_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104597","article-title":"The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection","volume":"171","author":"Painter","year":"2019","journal-title":"Antivir. Res"},{"issue":"7","key":"10.1016\/j.mrrev.2025.108533_bib49","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a040592","article-title":"Nucleotide Metabolism","volume":"13","author":"Chandel","year":"2021","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"7","key":"10.1016\/j.mrrev.2025.108533_bib50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S1473-3099(23)00118-4","article-title":"Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system","volume":"23","author":"Lewnard","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"15","key":"10.1016\/j.mrrev.2025.108533_bib51","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"13","key":"10.1016\/j.mrrev.2025.108533_bib52","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jama.2024.16432","article-title":"The latest research about paxlovid: effectiveness, access, and possible long covid benefits","volume":"332","author":"Rubin","year":"2024","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.mrrev.2025.108533_bib53","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1370\/afm.3120","article-title":"Nirmatrelvir\/ritonavir regimen for mild\/moderately severe COVID-19: a rapid review with meta-analysis and trial sequential analysis","volume":"22","author":"Okoli","year":"2024","journal-title":"Ann. Fam. Med"},{"key":"10.1016\/j.mrrev.2025.108533_bib54","doi-asserted-by":"crossref","unstructured":"Bhatia, A., et al., Effect of Nirmatrelvir\/Ritonavir (Paxlovid) on Hospitalization Among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C. medRxiv Preprint, 2024.","DOI":"10.1101\/2023.05.03.23289084"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108533_bib55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.mrrev.2025.108533_bib56","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jamainternmed.2024.2007","article-title":"Nirmatrelvir-ritonavir and symptoms in adults with postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial","volume":"184","author":"Geng","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s13063-021-05538-5","article-title":"Accelerated first-in-human clinical trial of EIDD-2801\/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2","volume":"22","author":"Holman","year":"2021","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108533_bib58","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mrrev.2025.108533_bib59","unstructured":"Hodowanec, A.C., Harrington, Patrick R., Rear, Julian J.O. and Struble, Kimberly A. Emergency Use Authorization (EUA) for Molnupiravir 200 mg capsules Center for Drug Evaluation and Research Review Memorandum, CEDER, Editor. 2023 (02\/17\/2023), FDA: Washington, DC. p. 13."},{"issue":"1","key":"10.1016\/j.mrrev.2025.108533_bib60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12985-023-01973-9","article-title":"An overview on the treatments and prevention against COVID-19","volume":"20","author":"Panahi","year":"2023","journal-title":"Virol. J."},{"issue":"9","key":"10.1016\/j.mrrev.2025.108533_bib61","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35077","article-title":"Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.mrrev.2025.108533_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102225","article-title":"Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation study","volume":"64","author":"Wan","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"12","key":"10.1016\/j.mrrev.2025.108533_bib63","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study","volume":"22","author":"Wong","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.mrrev.2025.108533_bib64","doi-asserted-by":"crossref","unstructured":"Bajema, K.L., et al., Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. medRxiv, 2022.","DOI":"10.1101\/2022.12.05.22283134"},{"key":"10.1016\/j.mrrev.2025.108533_bib65","article-title":"Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study","volume":"41","author":"Van Heer","year":"2023","journal-title":"Lancet Reg. Health West Pac."},{"issue":"12","key":"10.1016\/j.mrrev.2025.108533_bib66","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann. Intern Med"},{"issue":"3","key":"10.1016\/j.mrrev.2025.108533_bib67","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1093\/cid\/ciac481","article-title":"Rebound phenomenon after nirmatrelvir\/ritonavir treatment of coronavirus disease 2019 (COVID-19) in high-risk persons","volume":"76","author":"Ranganath","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.mrrev.2025.108533_bib68","doi-asserted-by":"crossref","unstructured":"Wang, L., et al., COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022. medRxiv, 2022.","DOI":"10.1101\/2022.06.21.22276724"},{"issue":"6","key":"10.1016\/j.mrrev.2025.108533_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28889","article-title":"Comparative efficacy and safety of nirmatrelvir\/ritonavir and molnupiravir for COVID-19: a systematic review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J. Med Virol."},{"key":"10.1016\/j.mrrev.2025.108533_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae213","article-title":"Combined treatment of severe acute respiratory syndrome coronavirus 2 reduces molnupiravir-induced mutagenicity and prevents selection for nirmatrelvir\/ritonavir resistance mutations","author":"Zhou","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mrrev.2025.108533_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.mrrev.2023.108466","article-title":"Error-corrected next generation sequencing \u2013 promises and challenges for genotoxicity and cancer risk assessment","volume":"792","author":"Marchetti","year":"2023","journal-title":"Mutat. Res. \/Rev. Mutat. Res."},{"key":"10.1016\/j.mrrev.2025.108533_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104748","article-title":"Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite beta-D-N4-hydroxycytidine across the blood-placenta barrier","volume":"95","author":"Chang","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.mrrev.2025.108533_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.reprotox.2023.108475","article-title":"An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations","volume":"121","author":"Marikawa","year":"2023","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.mrrev.2025.108533_bib74","unstructured":"Cavazzoni, P.A., M.D., Lagevrio Letter of Authorization, in Emergency Use Authorization 108, U. FDA, Editor. 2023, US FDA: Washington, DC."},{"key":"10.1016\/j.mrrev.2025.108533_bib75","first-page":"1747","article-title":"Hypoxanthine-guanine phosphoribosyltransferase reporter gene mutation for analysis of in vivo clonal amplification in patients with HTLV type 1-associated Myelopathy\/Tropical spastic paraparesis","volume":"16","author":"Albertini","year":"2000"},{"issue":"2","key":"10.1016\/j.mrrev.2025.108533_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13020309","article-title":"Molnupiravir: a versatile prodrug against SARS-CoV-2 variants","volume":"13","author":"Teli","year":"2023","journal-title":"Metabolites"}],"container-title":["Mutation Research - Reviews in Mutation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574225000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1383574225000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:30:17Z","timestamp":1748363417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1383574225000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":76,"alternative-id":["S1383574225000043"],"URL":"https:\/\/doi.org\/10.1016\/j.mrrev.2025.108533","relation":{},"ISSN":["1383-5742"],"issn-type":[{"value":"1383-5742","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tale of two drugs: Molnupiravir and Paxlovid","name":"articletitle","label":"Article Title"},{"value":"Mutation Research - Reviews in Mutation Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mrrev.2025.108533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108533"}}